Naoko Nakazawa

Title: Naoko Nakazawa: Innovator in Cancer Treatment

Introduction

Naoko Nakazawa is a prominent inventor based in Kudamatsu, Japan. She has made significant contributions to the field of cancer treatment through her innovative research and development of medical technologies. Her work focuses on improving the efficacy and safety of anticancer drugs.

Latest Patents

Naoko Nakazawa holds a patent for a method and kit designed to determine the risk of adverse effects associated with irinotecan, a synthetic anticancer drug. The patent, titled "Kits and method for determining the risk of adverse effects of irinotecan comprising hybridizing pairs of nucleic acid probes," involves detecting polymorphisms in the TATA box within the promoter region of the UDP-glucuronosyl transferase gene. This method aims to enhance patient safety by identifying individuals at risk of experiencing adverse effects from irinotecan treatment. She has 1 patent to her name.

Career Highlights

Throughout her career, Nakazawa has worked with notable organizations, including Toyo Kohan Co., Ltd. and Yamaguchi University. Her experience in these institutions has allowed her to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Naoko Nakazawa has collaborated with esteemed colleagues such as Masaaki Oka and Shouichi Hazama. These partnerships have furthered her research and development efforts in the medical field.

Conclusion

Naoko Nakazawa's innovative work in cancer treatment exemplifies her dedication to improving patient outcomes. Her contributions to the understanding of irinotecan's effects highlight the importance of personalized medicine in oncology.